Arigene Will Merge With Trimeris | October 12, 2009 Issue - Vol. 87 Issue 41 | Chemical & Engineering News
Volume 87 Issue 41 | p. 26 | Concentrates
Issue Date: October 12, 2009

Arigene Will Merge With Trimeris

Department: Business
Keywords: biotechnology, merger, antiviral drugs

South Korea’s Arigene will acquire Tri­meris through an $81 million stock offering. The offering price of $3.60 per share is a 40% premium on the price of Tri­meris’ stock on Oct. 1. Durham, N.C.-based Trimeris develops antiviral drugs and is the originator of the HIV fusion inhibitor Fuzeon, which is sold by Roche. Arigene is a medical equipment manufacturer looking to expand into the broader biotechnology industry.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment